403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
GT Biopharma Inc
(MENAFN- Baystreet) 11:21 AM EST - GT Biopharma Inc : Today announced that enrollment in the dose escalation cohorts of the Phase 1 trial, evaluating GTB-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic malignancies, is well on track. GT Biopharma Inc
shares N are trading off $0.02 at $0.72.
Full Press Release:
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment